logo

Last Update

This profile was last updated on 5/18/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Patrick McGovren?

Patrick McGovren

Principal

J Patrick McGovren LLC

Direct Phone: (269) ***-****direct phone

Email: p***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Research Director, Clinical Pharmacology, Medical Development

Pfizer Inc


Affiliations

RealBio Technology Inc

Scientific Advisory Board Member


ProNAi Therapeutics , Inc.

Vice President, Preclinical Development


Education

Ph.D.


Web References(14 Total References)


Scientific Advisors

www.nanomedpharm.com [cached]

J. Patrick McGovren, Ph.D. is a longtime and well-known cancer research specialist, holding senior positions in big pharma oncology departments, as well as extensive consulting experience.
He was involved in the discovery and/or development of nine clinically evaluated anti-tumor drugs and has significant clinical trial operations and IND/NDA submission experience. Currently, Dr. McGovren is VP, Preclinical Development of ProNai Therapeutics, Inc., an emerging biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi®, to advance a next generation of therapies for patients with cancer and other complex genetic diseases. Prior to joining ProNAi, Dr. McGovren was most recently Research Director, Clinical Pharmacology, Medical Development at Pfizer, following a term as Clinical Research Manager,Oncology Medical Affairs at Pharmacia. Between 1976 and 2000, Dr. McGovren held numerous senior research and management posts at Pharmacia & Upjohn.


RealBio® - Learn More Information About RealBio® Technology, Inc.

www.realbiotechnology.com [cached]

J. Patrick McGovren, Ph.D.
Dr. McGovren has a Ph.D. in Pharmaceutical Sciences and extensive pharmaceutical industry and start-up experience in the preclinical and clinical development of anticancer drugs. He was deeply involved in the discovery and/or development of 10 clinically evaluated antitumor drugs. Pat was a key advocate for The Upjohn Company's successful in-licensing of irinotecan which was marketed as Camptosarâ„¢ Injection and became a significant colorectal cancer product with $500 MM per annum US sales. During his laboratory career, Dr. McGovren was responsible for screening and detailed evaluation of test compounds in mouse tumor models as well as the preclinical pharmacology and pharmacokinetics of lead compounds. Later he worked as a clinical operations manager for phase IV/post-marketing studies, and then moved into Pharmacia's clinical pharmacology group. He has prepared IND and NDA preclinical and clinical pharmacology sections and participated in resolving numerous clinical pharmacology-related regulatory issues.


ProNAi Therapeutics - Employing DNA to Silence Disease

www.pronai.com [cached]

J. Patrick McGovren, PhD
VP, Preclinical Development Dr. McGovren is a longtime and well-known cancer research specialist, holding senior positions in big pharma oncology departments, as well as extensive consulting experience. Prior to joining ProNAi, Dr. McGovren was most recently Research Director, Clinical Pharmacology, Medical Development at Pfizer, following a term as Clinical Research Manager, Oncology Medical Affairs at Pharmacia. Between 1976 and 2000, Dr. McGovren held numerous senior research and management posts at Pharmacia & Upjohn.


Scientific Advisory Board

www.AzoRx.com [cached]

J. Patrick McGovren, Ph.D.Chief Scientific Officer AzoRx, Inc.


Nanomed Pharm :: Read our News :: John B. Landis, Ph.D. Joins SAB

www.nanomedpharm.com [cached]

In addition to Dr. Landis, key members serving on NanoMed's Scientific Advisory Board include: Russell J. Mumper, Ph.D., NanoMed co-founder, the John A. McNeill Distinguished Professor in the Molecular Pharmaceutics Division in the School of Pharmacy, and the first Director of the Center for Nanotechnology in Drug Delivery at The University of North Carolina at Chapel Hill; Michael Jay, Ph.D., NanoMed co-founder and professor in the Molecular Pharmaceutics division at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy; J. Patrick McGovren, Ph.D., VP, Preclinical Development of ProNai Therapeutics, Inc. and former Research Director, Clinical Pharmacology, Medical Development at Pfizer, Inc.; Charles Bibart, Ph.D., former Group Vice President - Active Pharmaceutical Ingredients for Pharmacia Corporation; and Douglas R. Morton, Jr., Ph.D.,formerGroup Vice President, Technology Acquisitions & Operations for Discovery Research in Pharmacia Corporation.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory